TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease

Digestive and Liver Disease

Volumn 44, Issue 9, 2012, Pages 780-787

  Rath, Timo ^a   Menendez, Katrin Menendez ^a   Kügler, Marion ^a   Hage, Lisa ^a   Wenzel, Christian ^a   Schulz, Richard ^a   Graf, Jürgen ^b,c   Nährlich, Lutz ^d   Roeb, Elke ^a   Roderfeld, Martin ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Deutsche Lufthansa AG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Extracellular matrix; Liver fibrosis; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

GELATINASE B; HYALURONIC ACID; PROCOLLAGEN; PROCOLLAGEN III PEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS ASSOCIATED LIVER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ELASTOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCHOOL CHILD; TRANSIENT ELASTOGRAPHY;

ADIPOKINES; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; AREA UNDER CURVE; BILIRUBIN; BIOLOGICAL MARKERS; CHILD; CYSTIC FIBROSIS; ELASTICITY IMAGING TECHNIQUES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPERTENSION, PORTAL; LECTINS; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 9; PLATELET COUNT; PROTHROMBIN TIME; ROC CURVE; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; YOUNG ADULT;

EID: 84864412903     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.04.008     Document Type: Article

References (36)

1. Moyer K., Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Current Opinion in Gastroenterology 2009, 25:272-278.
2. Debray D., Kelly D., Houwen R., et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. Journal of Cystic Fibrosis 2011, 10(Suppl. 2):S29-S36.
3. Potter C., Hogan M.J., Henry-Kendjorsky K., et al. Safety of pediatric percutaneous liver biopsy performed by interventional radiologists. Journal of Pediatric Gastroenterology and Nutrition 2011, 53:202-206.
4. Castera L., Negre I., Samii K., et al. Pain experienced during percutaneous liver biopsy. Hepatology 1999, 30:1529-1530.
5. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
6. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. New England Journal of Medicine 2001, 344:495-500.
7. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
8. Colloredo G., Guido M., Sonzogni A., et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. Journal of Hepatology 2003, 39:239-244.
9. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. American Journal of Gastroenterology 2002, 97:2614-2618.
10. Malbrunot-Wagner A.C., Bridoux L., Nousbaum J.B., et al. Transient elastography and portal hypertension in pediatric patients with cystic fibrosis transient elastography and cystic fibrosis. Journal of Cystic Fibrosis 2011.
11. Witters P., De Boeck K., Dupont L., et al. Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. Journal of Cystic Fibrosis 2009, 8:392-399.
12. Menten R., Leonard A., Clapuyt P., et al. Transient elastography in patients with cystic fibrosis. Pediatric Radiology 2010, 40:1231-1235.
13. Gressner A.M., Gao C.F., Gressner O.A. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World Journal of Gastroenterology 2009, 15:2433-2440.
14. Flume P.A., O'Sullivan B.P., Robinson K.A., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine 2007, 176:957-969.
15. Kerem E., Conway S., Elborn S., et al. Standards of care for patients with cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 2005, 4:7-26.
16. Tajiri T., Yoshida H., Obara K., et al. General rules for recording endoscopic findings of esophagogastric varices (2nd ed.). Digestive Endoscopy 2010, 22:1-9.
17. Colombo C., Battezzati P.M., Crosignani A., et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002, 36:1374-1382.
18. Lindblad A., Glaumann H., Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30:1151-1158.
19. Colombo C., Russo M.C., Zazzeron L., et al. Liver disease in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2006, 43(Suppl. 1):S49-S55.
20. Breton E., Bridoux-Henno L., Guyader D., et al. Value of transient elastography in noninvasive assessment in children's hepatic fibrosis. Archives de Pediatrie 2009, 16:1005-1010.
21. Kamal S.M., Turner B., He Q., et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006, 43:771-779.
22. Rath T., Roderfeld M., Guler C., et al. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology 2011, 46:1369-1380.
23. Roeb E., Purucker E., Breuer B., et al. TIMP expression in toxic and cholestatic liver injury in rat. Journal of Hepatology 1997, 27:535-544.
24. Benyon R.C., Iredale J.P., Goddard S., et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996, 110:821-831.
25. Yata Y., Takahara T., Furui K., et al. Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease. Journal of Hepatology 1999, 30:425-432.
26. Lichtinghagen R., Bahr M.J., Wehmeier M., et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clinical Science (London) 2003, 105:373-382.
27. Boker K.H., Pehle B., Steinmetz C., et al. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepato-Gastroenterology 2000, 47:812-819.
28. Sokol R.J., Durie P.R. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. Journal of Pediatric Gastroenterology and Nutrition 1999, 28(Suppl. 1):S1-S13.
29. Lewindon P.J., Shepherd R.W., Walsh M.J., et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011, 53:193-201.
30. Mueller-Abt P.R., Frawley K.J., Greer R.M., et al. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 2008, 7:215-221.
31. Lenaerts C., Lapierre C., Patriquin H., et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. Journal of Pediatrics 2003, 143:343-350.
32. Friedrich-Rust M., Ong M.F., Martens S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-974.
33. Gomez-Dominguez E., Mendoza J., Rubio S., et al. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics 2006, 24:513-518.
34. Scott-Jupp R., Lama M., Tanner M.S. Prevalence of liver disease in cystic fibrosis. Archives of Disease in Childhood 1991, 66:698-701.
35. Lamireau T., Monnereau S., Martin S., et al. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. Journal of Hepatology 2004, 41:920-925.
36. Gaskin K.J., Waters D.L., Howman-Giles R., et al. Liver disease and common-bile-duct stenosis in cystic fibrosis. The New England Journal of Medicine 1988, 318:340-346.